Pages that link to "Q42990702"
Jump to navigation
Jump to search
The following pages link to Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. (Q42990702):
Displaying 50 items.
- Antiviral drugs for viruses other than human immunodeficiency virus (Q24635330) (← links)
- KASL clinical practice guidelines: management of hepatitis C (Q26752471) (← links)
- Replicative Homeostasis III: implications for antiviral therapy and mechanisms of response and non-response (Q27478215) (← links)
- Improving the Diagnosis of Acute Hepatitis C Virus Infection with Expanded Viral Load Criteria (Q27489863) (← links)
- Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection (Q27490862) (← links)
- Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study (Q27491349) (← links)
- Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response (Q28481489) (← links)
- Mechanism of action of interferon and ribavirin in treatment of hepatitis C (Q29619805) (← links)
- Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous viral clearance, and delayed treatment with 12 weeks of pegylated interferon alfa-2a (Q33396464) (← links)
- Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C (Q33955516) (← links)
- Acute hepatitis C. (Q34013032) (← links)
- Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection (Q34714349) (← links)
- Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection (Q34779758) (← links)
- Hepatitis C virus virology and new treatment targets (Q34974042) (← links)
- Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users (Q35053344) (← links)
- Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort (Q36063808) (← links)
- Development of prophylactic and therapeutic vaccines against hepatitis C virus (Q36198667) (← links)
- Current therapy for hepatitis C. (Q36263113) (← links)
- Pegylated interferon and ribavirin treatment for hepatitis C virus infection (Q36443698) (← links)
- Treating viral hepatitis C: efficacy, side effects, and complications (Q36564615) (← links)
- Improving anti-hepatitis C virus therapy (Q36569749) (← links)
- Present and future therapy for hepatitis C virus (Q36670887) (← links)
- IFN-α subtypes: distinct biological activities in anti-viral therapy. (Q36675798) (← links)
- Acute hepatitis C in an HIV-infected patient: a case report and review of literature (Q36780300) (← links)
- Role of IL28B gene polymorphism and cell-mediated immunity in spontaneous resolution of acute hepatitis C. (Q37111632) (← links)
- Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis (Q37161958) (← links)
- Acute hepatitis C: a systematic review (Q37162708) (← links)
- Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment (Q37255644) (← links)
- Interferons and their use in persistent viral infections (Q37338989) (← links)
- Acute hepatitis C and HIV coinfection (Q37635433) (← links)
- Treatment of hepatitis C virus infection in patients with end-stage renal disease. (Q37831965) (← links)
- Treatment of acute HCV infection (Q37855530) (← links)
- Interferon therapy of acute hepatitis C in dialysis patients: meta-analysis (Q38050166) (← links)
- Natural killer cells in hepatitis C virus infection. (Q38061192) (← links)
- Acute hepatitis C: management in the rapidly evolving world of HCV. (Q38183312) (← links)
- Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment (Q38195262) (← links)
- APASL consensus statements and management algorithms for hepatitis C virus infection. (Q38552131) (← links)
- Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations. (Q39084627) (← links)
- Immunomodulation by hepatitis C virus-derived proteins: targeting human dendritic cells by multiple mechanisms (Q39712175) (← links)
- Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study (Q40355356) (← links)
- Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. (Q41855937) (← links)
- Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin (Q42232261) (← links)
- Making the best of a bad situation: early chronic nosocomial HCV infection (Q42997121) (← links)
- Duration of peginterferon therapy in acute hepatitis C: a randomized trial (Q42999619) (← links)
- Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. (Q43032166) (← links)
- Acute hepatitis C in Korea: different modes of infection, high rate of spontaneous recovery, and low rate of seroconversion (Q43036767) (← links)
- Spontaneous loss of hepatitis C virus RNA from serum is associated with genotype 1 and younger age at exposure (Q43037174) (← links)
- Transmission of hepatitis C virus by needle-stick injury in community settings (Q43041155) (← links)
- Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office (Q44097379) (← links)
- Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study (Q44543175) (← links)